3 Biotech Stocks With a Lot to Prove at ASH 2019
https://www.fool.com/investing/2019/12/02/3-biotech-stocks-with-a-lot-to-prove-at-ash-2019.aspx?source=iedfolrf0000001
Dec 02, 2019 - These companies have some important presentations scheduled for the last big oncology conference of the year.
0
Top Research Reports for Merck, Eli Lilly & Charter Communications
http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-ZC-FT-research_daily-643445
Nov 27, 2019 - Top Research Reports for Merck, Eli Lilly & Charter Communications
0
Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
http://www.zacks.com/stock/news/629205/alkermes-submits-nda-to-fda-for-schizophrenia-bipolar-i-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-629205
Nov 20, 2019 - Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.
0
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |
| SNY | Sanofi | NYSE | $43.75 | $109.14B |
| ABT | Abbott Laboratories | NYSE | $67.67 | $118.71B |
| BMY | Bristol-Myers Squibb Company | NYSE | $61.3 | $100.03B |
| GSK | GlaxoSmithKline PLC | NYSE | $39.21 | $97.25B |